MDACC Study No:2012-0707 ( NCT No: NCT01578707)
Title:A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Principal Investigator:William G. Wierda
Treatment Agent:Ibrutinib; Ofatumumab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if ibrutinib, also known
as PCI-32765, can help control the disease when compared to ofatumumab in
patients with CLL or SLL. Researchers also want to learn about the safety of
ibrutinib and how long it stays in the blood.

Ibrutinib is designed to block a protein in cancer cells that may kill or stop
them from growing.

Ofatumumab is designed to bind to the surface of a type of white blood cells.
This may cause cancer cells that come from these white blood cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase III
Treatment Agents:Ibrutinib
Treatment Location:Only at Other Sites
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics, Incorporated
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults